Free Trial
NYSE:CLDI

Calidi Biotherapeutics 8/13/2024 Earnings Report

Calidi Biotherapeutics logo
$0.48 -0.02 (-3.63%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$0.49 +0.01 (+2.92%)
As of 05/5/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Calidi Biotherapeutics EPS Results

Actual EPS
-$1.40
Consensus EPS
-$1.43
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Calidi Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Calidi Biotherapeutics Announcement Details

Quarter
Time
TAS
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Calidi Biotherapeutics Earnings Headlines

Our $1 AI stock to buy right now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so. Musk has been quietly creating one of the most ambitious AI ventures in history.
Calidi reports inducement grant unders NYSE American guide
Calidi appoints Eric Poma as CEO, director
See More Calidi Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Calidi Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calidi Biotherapeutics and other key companies, straight to your email.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE:CLDI), a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

View Calidi Biotherapeutics Profile

More Earnings Resources from MarketBeat